Morgan Stanley lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $5 from $8 and keeps an Equal Weight rating on the shares. The firm revised its model following the company’s recent pipeline prioritizations, cost reductions, 20% workforce reduction and updated cash burn guidance.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Cautious Outlook on Recursion Pharmaceuticals Amid Strategic Restructuring and Cash Management Challenges
- Largest borrow rate increases among liquid names
- Recursion Pharmaceuticals Announces Workforce Reduction Strategy
- Recursion Pharmaceuticals announces 20% workforce reduction
- Unusually active option classes on open June 9th